No Data
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024
CANTON, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions
Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Stock Is Going Strong: Have Financials A Role To Play?
Is Organogenesis a Hidden Gem in the Biotech Sector?
Lake Street Initiates Organogenesis(ORGO.US) With Buy Rating, Announces Target Price $5
Lake Street analyst Brooks O'Neil initiates coverage on $Organogenesis(ORGO.US)$ with a buy rating, and sets the target price at $5.According to TipRanks data, the analyst has a success rate of 43.3%
Organogenesis Holdings Initiated at Buy by Lake Street
Organogenesis Holdings Initiated at Buy by Lake Street
Express News | Lake Street Initiates Coverage On Organogenesis Hldgs With Buy Rating, Announces Price Target of $5